

(Translation)

Minutes of 2025 Annual General Meeting of Shareholders

Inter Pharma Public Company Limited

Meeting Time & Venue

Inter Pharma Public Company Limited ("the Company") held the 2025 Annual General Meeting of Shareholders on Monday, April 28, 2025 at 14.00 hrs., via electronic broadcast live (E-Meeting) from the meeting room of Inter Pharma Public Company Limited, 140/9 ITF Tower, 9 Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500

Meeting started at 14.00 hrs.

Clinical Professor Emeritus Dr. Udom Kachintorn, Chairman of the Board of Directors, presided as the Chairman of the meeting thanked the shareholders for attending the 2025 Annual General Meeting of Shareholders of the Company via electronic means (E-Meeting) only. The Chairman opened the meeting and assigned Ms. Chompunuch Meevang, the Company Secretary, as the moderator of the meeting.

The Company Secretary informed the meeting that the 2025 Annual General Meeting of Shareholders will be conducted via electronic means (E-Meeting) only. The Company has complied with the Royal Decree on Electronic Conferencing B.E. 2020 and the Notification of the Ministry of Digital Economy and Society on Security Standards of Electronic Conferencing B.E. 2020. In this meeting the company has assigned Quidlab Co., Ltd., a service provider that has received a certificate for the electronic conferencing control system. According to the information security standard of the Electronic Transactions Development Agency's Conference Control System Register Counting votes in the Annual General Meeting of Shareholders, including organizing the meeting via electronic media system (E-Meeting) and the meeting was recorded in video.

Quorum

The Company Secretary informed the meeting that the meeting, 11 shareholders were presence in person, representing 211,197,207 shares, and 23 shareholders by proxy, representing 140,554,545 shares. In total, 34 shareholders, holding a total of 351,751,752 shares, equivalent to 58.1077% of the common shares, which constituted a quorum pursuant to the Company's Articles of Association no. 39 and representing at least one-thirds of shares distributed shall be required.

The Company Secretary introduced to the meeting, the directors, managements, auditors from EY Office Limited and representatives of the auditor being witnesses. These persons were as follows:

Directors and Management attending the meeting at the meeting venue:

- | | | |
|----|---|---|
| 1. | Clinical Professor Emeritus Dr. Udom Kachintorn | Chairman of the Board of Directors/
Independent Director/ Chairman of the
Corporate Governance and Sustainable
Development Committee |
| 2. | Dr. Pao Sriprasertsuk | Independent Director/ Audit Committee/
Nomination and Remuneration Committee/
Corporate Governance and Sustainable |
| 3. | Dr. Trinnawat Thanitnithiphan* | Director/ Nomination and Remuneration
Committee/ Risk Management Committee/
Chairman of Executive Committee and CEO |

Directors attending the meeting via electronic media:

- | | | |
|----|--|---|
| 1. | Prof. Dr. Sansanee Chaiyaroj* | Independent Director/ Audit Committee/
Chairman of the Risk Management
Committee/ Corporate Governance and
Sustainable Development Committee |
| 2. | Mr. Kamtorn Sila-on* | Independent Director/ Chairman of the Audit
Committee/ Chairman of Nomination and
Remuneration Committee / Corporate
Governance and Sustainable Development
Committee |
| 3. | Dr. Pao Sriprasertsuk | Independent Director/ Audit Committee/
Nomination and Remuneration Committee/
Corporate Governance and Sustainable
Development Committee |
| 4. | Dr. Nat Ativitavas* | Director |
| 5. | Dr. Yutthana Suwannachot* | Director |
| 6. | Ms. Napaporn Dechakarot* | Director/ Risk Management Committee/
Executive Committee and COO |
| 7. | Mrs. Apimon Posri* | Director/ Executive Committee and Human
Resource Director |

Directors attending the meeting: All 9 persons (equivalent to 100% of the total Board members)

Management and Others Related:

- | | | |
|----|---|-------------------------------------|
| 1. | Ms. Supaporn Rerkpitakpanich | Group Accounting & Finance Director |
| 2. | Ms. Chatkaew Krudkosol | Acting to Chief Finance Officer |
| 3. | Ms. Chompunuch Meevang | Company Secretary |

Auditors from EY Office Limited:

Ms. Siriwan Nitdamrong

Representatives of the Auditor being Witnesses during the Voting Process:

Ms. Jintana Umpornpa-nga

In the meantime, the Company Secretary informed the meeting that the 2025 Annual General Meeting of Shareholders has 8 agenda items as detailed in the invitation letter sent to all shareholders by the Company and has been published on the Company's website. The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during October 1, 2024 - December 31, 2024, in which there were no shareholders proposing agendas and nominate names of persons to be considered for election as a director.

The Company Secretary has clarified the details of the voting method and raising questions can be summarized as follows:

1. In voting of today's meeting, each shareholder has the right to vote which equivalent to the number of shares held. By counting 1 share equal to 1 vote and the shareholders have the right to vote on each agenda to agree, disagree or abstain in just one way or another.
2. In counting the votes, the Company counts the votes of the shareholders who register to attend the meeting via electronic media by pressing one of the voting buttons; agree, disagree or abstain in each agenda at any time when the agenda is not closed. After the agenda is closed, if the shareholders do not press the voting button, the system will consider that the shareholders is agreed and cannot change the voting.
3. In addition, for the proxies whose voters have already specified their voting for each agenda item in the proxy form, the Company has counted your votes from the proxy form. This is for the convenience of shareholders.
4. For reading the voting results in each agenda, the Chairman and or the Company Secretary will inform the meeting of the voting results of each agenda. The results of the votes will be the votes that include the votes of the shareholders who attend the meeting, both in person and by proxy. Each agenda will use the number of shares of the latest attendees in that agenda.
5. In each agenda, there will be an opportunity for shareholders to ask questions by sending questions through typing in texts or sending voice messages. In doing so, the shareholders have to click on the Question Menu, type your message in the text box. If shareholders have experienced any problems during the electronic meeting, please contact Quidlab Company Limited at 02-013-4322 or email: info@quidlab.com.

In this regard, The Company reserves the right to consider and select questions as appropriate in case of a large number of questions being sent into the system, if there are any questions that cannot be answered during the meeting due to limited time. The Company will consider collecting, answering and disclosing in

the minutes of the shareholders' meeting, which the company will disseminate through the information system of the Stock Exchange of Thailand and on the Company's website within 14 days from the date of the shareholders' meeting.

When shareholders are aware and have no other opinion on the voting method and asking questions as presented above, the Chairman shall proceed the meeting according to the agenda as follows:

Agenda 1 To certify the Minutes of the 2024 Annual General Meeting of Shareholders

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company prepares the minutes of the 2024 Annual General Meeting of Shareholders on April 26, 2024, The Board of Directors has considered the minutes had been duly and accurately recorded and reflected the resolutions passed by the said Shareholders' Meeting, the copies of which had been sent to the shareholders together with the notice of this Meeting as per Attachment No. 1.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item.

The Chairman proposed the meeting to consider approving the Minutes of the 2024 Annual General Meeting of Shareholders.

Meeting Resolution The meeting considered and unanimously resolved to certify the Minutes of the 2024 Annual General Meeting of Shareholders with the following votes:

Agree	352,643,652	votes	% equivalent to 100.0000
Disagree	0	votes	% equivalent to 0.0000
Abstain	0	votes	% equivalent to 0.0000

Remark: In this agenda, there were 3 more shareholders attending the meeting, totaling 892,000 shares, making a total of 37 shareholders attending the meeting, with 352,643,752 shares with voting rights, or 58.2551%.


Agenda 2 To acknowledge the operating results for the year ended 31 December 2024

The Chairman assigned Ms. Supaporn Rerkpitakpanich, Group Accounting & Finance Director, to inform the Meeting of the details regarding this agenda

Ms. Supaporn Rerkpitakpanich, Group Accounting & Finance Director, informed the Meeting that the Company's performance for the year 2024 is as follows:

The company reported total revenue from sales and services of 1,897 million baht, representing an increase of 116 million baht or 7% compared to the previous year. Gross profit amounted to 710 million baht, with a gross profit margin of 37%. Selling and administrative expenses totaled 649 million baht, accounting for 34% of total revenue from sales and services. This represents an increase of 82 million baht or 14% from the

previous year. Net profit was recorded at 38 million baht, with a net profit margin of 2%, representing a decrease of 1.3% from the previous year. The revenue breakdown by business segment is as follows:



The Company would like to report on the progress of operations in 2024, which are detailed as follows:

- The Company moved IP securities to trade on the Stock Exchange of Thailand (SET) on August 1, 2024.
- In September, the Company acquired shares of Metta Medtech Co., Ltd. in the amount of 60 percent of the issued and paid-up registered capital, which is engaged in the business of distributing medical instruments and equipment, including rental and maintenance of such equipment and tools, as well as providing rehabilitation medicine and physical therapy services. And in October 2024, the name was changed to Inter Pharma Medtech Co., Ltd.
- Nakornpat Inter Co., Ltd. has renovated the hospital to be more modern and have better standards. On April 3, 2025, the company's directors visited Nakornpat Inter Hospital.
- Drug Care Co., Ltd. has expanded its branches. As of December 31, 2024, there are a total of 41 branches. In the first quarter of 2025, 5 more branches were opened.
- On April 1, 2025, the Company signed a cooperation agreement between the Company and Zhaoke Ophthalmology Company Limited ("Zhaoke"), a company listed on the Hong Kong Stock Exchange and a subsidiary of Lee's Pharmaceutical Holdings Limited. Zhaoke is a leading company in comprehensive eye care innovation, offering products such as eye drops for myopia, hyperopia, dry eye, and glaucoma. This collaboration establishes the Company as the exclusive distributor for Zhaoke's comprehensive eye care innovations in Thailand.

The Company Secretary inform that the Company is highly emphasize on anti- corruption. The Company has created an anti-corruption policy to serve as a guideline for the conduct of directors, executives,

and employees of the Company. which must be strictly adhered to. If there are any clues about corruption or complaints related to the Company's business can be notified via email: comsec@interpharma.co.th or deliver by post to the Company's address. In the past, the Company has not found any complaints related to corruption or related to the Company's business.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions:

1. Mr. Rangsi Chuntharusmi, a shareholder, inquired about the scope of distribution under the exclusive agreement signed by IP. Specifically, he requested clarification on the countries where the exclusive rights apply.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, responded that the company has entered into an exclusive distribution agreement with Zhaoke Ophthalmology Company Limited, granting IP the exclusive rights to distribute products solely in Thailand. Additionally, there are potential future collaborations under consideration regarding the local manufacturing of eye drops for conditions such as myopia, hyperopia, and eye inflammation. Therefore, the exclusivity applies only within the territory of Thailand.

2. Ms. Araya Kingkaew, a shareholder, asked about the rental costs of various Lab Pharmacy branches. She observed that although staff presence remains steady, customer traffic appears to have declined, and she wished to know whether there are plans to manage or adjust related expenses.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, replied that the company continuously reviews the performance of each branch to assess profitability. If a branch is not profitable, improvement plans will be implemented; however, if there is no viable path forward, closure will be considered. Overall, most branches have been performing well. Nevertheless, one branch located within a PTT gas station in Nong Khaem was closed. Regarding the observation of reduced customer presence, he clarified that pharmacies typically see higher sales during evenings, weekends, and public holidays. This is because most of the company's pharmacies are located within shopping malls, which experience increased foot traffic during those periods.

3. Ms. Araya Kingkaew, a shareholder, recommended that the company should place greater emphasis on selecting employees who demonstrate a strong sense of customer service or the ability to make customers want to return for future services.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, expressed his appreciation for the valuable suggestions. He emphasized that service is a critical aspect of the organization. There are two key areas of focus: First, knowledge regarding diseases and medications, enabling staff to provide accurate advice and guidance. Second, the quality of service, which requires a strong service mindset. The organization is committed to developing all personnel under what we refer to as the "Service Model," which emphasizes friendliness, warm greetings, and welcoming customer interactions. Staff are trained to

inquire about drug allergies and other relevant information to ensure proper care. We continuously review and improve our service standards on a regular basis.

This agenda is for acknowledgement and therefore there is no voting.

Agenda 3 To approve the annual financial statements for the year ended 31 December 2024

The Chairman assigned Ms. Chatkaew Krudkosol, Acting to Chief Finance Officer, to inform the Meeting of the details regarding this agenda

Ms. Chatkaew Krudkosol, Acting to Chief Finance Officer, informed the Meeting that the Company has prepares the Financial Statements for the year ended December 31, 2024, as duly audited and certified by the auditor from EY Office Limited and reviewed by the Audit Committee. The summary of the Company's financial status and performance during the year 2024 is as follows:

		Consolidated Financial Statement		Separate Financial Statement	
		2024	2023	2024	2023
Total Assets	(Million Baht)	3,020.56	2,952.37	2,225.68	2,239.25
Total Liabilities	(Million Baht)	886.40	834.64	298.09	323.58
Total Revenue	(Million Baht)	1,911.95	1,798.77	653.47	619.91
Profit (Loss) for the year*	(Million Baht)	37.68	58.90	25.31	58.20
Earning (Loss) per share	(Baht : Share)	0.062	0.084	0.042	0.096

The Chairman gave the shareholders an opportunity to ask questions and express their opinions, There were no shareholders inquiring or expressing opinions on this agenda item.

The Chairman proposed the meeting to approve the annual financial statements for the year ended 31 December 2024.

Meeting Resolution The meeting considered and resolved to approved the annual financial statements for the year ended 31 December 2024 as proposed with the following votes:

Agree	355,757,614	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	100	votes	% equivalent to	0.0000

Remark: In this agenda, there were 3 more shareholders attending the meeting, totaling 3,113,962 shares, making a total of 40 shareholders attending the meeting, with 355,757,714 shares with voting rights, or 58.7695%.

Agenda 4 To consider and approve the allocation of legal reserve and omitted dividend payment for operating results in 2024

The Chairman assigned Ms. Chompunuch Meevang, Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 115 of the Public Limited Company Act and Article 51 of the Company's Articles of Association, provide that no dividends shall be paid other than out of profits. The Company's policy is to pay dividends at the rate of not less than 50 percent of the net profits after deducting the legal reserves and, provided that dividend payment will be subjected to the Company's cash flow, investment plan, conditions and terms of agreements to which the Company is bound, as well as the necessity and other appropriateness in the future.

And according to Section 116 of the Public Limited Company Act and Clause 53 of the Company's Articles of Association, the Company must allocate part of the annual net profit as reserve fund in an amount not less than five percent of the annual net profit less the sum of accumulated loss brought forward (if any) until the reserve fund amounts to be not less than ten percent of the registered capital.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the allocation of net profit for the year 2024 in the amount of 1.2 Million Baht as the Company's legal reserve and approve the omitted dividend payment for operating results in 2024 to be used as the Company's working capital.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. There were no shareholders inquiring or expressing opinions on this agenda item.

The Chairman proposed the meeting to approve the allocation of legal reserve and omitted dividend payment for operating results in 2024.

Meeting Resolution The meeting considered and resolved to approve the allocation of legal reserve and omitted dividend payment for operating results in 2024 with the following:

Agree	355,757,714	votes	% equivalent to 100.0000
Disagree	0	votes	% equivalent to 0.0000
Abstain	0	votes	% equivalent to 0.0000

Agenda 5 To consider and approve the appointment of directors replacing those due to retire by rotation

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that the Section 71 of the Public Limited Company Act and Clause 21 of the Company's Articles of Association, stipulates that in every annual general meeting of shareholders one third (1/3) of the total number of Directors shall vacate office. If the number of Directors

vacating office cannot be exactly divided by one-third (1/3), the number that is similar to one-third (1/3) shall be used. However, Directors who due to retire can be re-elected to return to the position again.

Currently, the Company has a total of 9 directors. Therefore, at the 2025 Annual General Meeting of Shareholders, 3 directors will be required to retire by rotation. The names of the directors due to retire are as follows:

- | | | |
|----|-----------------------|---|
| 1. | Mr. Kamtorn Sila-On | Independent Director, Chairman of the Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee |
| 2. | Dr. Pao Sriprasertsuk | Independent Director, Audit Committee, Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee |
| 3. | Mrs. Apimon Posri | Director and Executive Committee |

The Company provides an opportunity for shareholders to propose agendas and nominate candidates to be elected as directors during October 1, 2024 – December 31, 2024, in which there were no shareholders proposing agendas and names of persons to be considered for election as a director.

The Nomination and Remuneration Committee (excluding the stakeholders) has carefully reviewed before presenting to the Board of Directors and to propose to the Annual General Meeting of Shareholders for election directors, considering the qualifications of directors as specified in the relevant laws, the Company's regulations, proportion and qualification of Independent Directors according to the definition of Independent Director of the Company, as well as knowledge, capabilities and experience that are useful to the Company's business. The Nomination and Remuneration Committee deemed it appropriate to propose the appointment of Mr. Kamtorn Sila-On, Dr. Pao Sriprasertsuk and Mrs. Apimon Posri to return to serve as Directors for another term. The Nomination and Remuneration Committee considered that all candidates nominated have all qualifications as specified by relevant regulations and suitable for the business, and the candidates nominated as independent directors are fully qualified in accordance with the law and regulations relating to independent directors and are able to provide opinions independently.

The Board of Directors (excluding stakeholders) considered the list of nominated persons, which have been carefully screened and considered by the Nomination and Remuneration Committee, and deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint 3 directors, namely Mr. Kamtorn Sila-On, Dr. Pao Sriprasertsuk and Mrs. Apimon Posri to return to serve as Directors for another term. The Board of Directors considered that the candidates nominated as an Independent Directors have all qualifications as specified by relevant regulations and are able to provide opinions independently. Profiles and working experiences of the candidates nominated for election as the directors in place of those who retire by rotation in Attachment No.3.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda.

The Company Secretary informed of the voting procedures for the election of directors, as detailed below.

Clause 19 of the Company's Articles of Association stipulates the director voting procedures as follows:

- (1) A shareholder shall have one vote for each share he holds or represents.
- (2) The shareholders shall vote for each individual candidate nominated for directors, but not exceeding the number of directors required for that election. The vote shall not be distributed.
- (3) The candidates shall be ranked in order descending from the highest number of votes received to the lowest, and shall be appointed as directors in that order until all of the director positions are filled. Where the votes cast for candidates in descending order are tied, which would otherwise cause the number of directors to be exceeded, the remaining appointment shall be made by the Chairman of the Meeting who shall have a casting vote.

For Agenda 5, the Meeting was requested to consider the candidates on an individual basis in the order as appeared in Agenda 5 of the Notice of the meeting, which showed the list of all nominated candidates.

The Company Secretary then proposed that the shareholders vote on the candidates on an individual basis, whereby this year there were four candidates nominated for election as directors to replace the directors due to retire by rotation, equivalent to the number of directors

Meeting Resolution The meeting considered and resolved to approve the appointment of directors replacing those due to retire by rotation with the following votes:

(1) Mr. Kamtorn Sila-On		Independent Director	
Agree	355,757,714 votes	% equivalent to	100.0000
Disagree	0 votes	% equivalent to	0.0000
Abstain	0 votes	% equivalent to	0.0000
(2) Dr. Pao Sriprasertsuk		Independent Director	
Agree	355,757,714 votes	% equivalent to	100.0000
Disagree	0 votes	% equivalent to	0.0000
Abstain	0 votes	% equivalent to	0.0000
(3) Mrs. Apimon Posri		Director	
Agree	355,757,714 votes	% equivalent to	100.0000
Disagree	0 votes	% equivalent to	0.0000
Abstain	0 votes	% equivalent to	0.0000

Agenda 6 To consider and approve the remuneration of directors for the year 2025

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Article 26 of the Company's Articles of Association, Directors are eligible for remuneration in forms of rewards, meeting allowance, gratuity, bonus or other benefit according to the resolution of the Shareholders' Meeting by not less than two-thirds (2/3) of the total number of votes of the shareholders attending the meeting and having the right to vote.

The Nomination and Remuneration Committee conducted a survey on remuneration for the Board of Directors and sub-committees for the year 2025, considering the suitability from the scope of duties and responsibilities, the responsibilities and performance of the Board of Directors and each sub-committee, business expansion, the Company's performance and comparative information with other companies in the same industry with similar size and nature of the business and considered appropriate to maintain the remuneration of the Board of Directors and sub-committees, including monthly remuneration and meeting allowance for the year 2025 (proposed year) at the same rate as year 2024.

The Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the remuneration of the Board of Directors and sub-committees for the year 2025 (proposed year) as proposed by the Nomination and Remuneration Committee who had taken into consideration various factors and criteria as follows:

Position	2025 (proposed year)	2024
Monthly remuneration (person : month) For non-executive directors <ul style="list-style-type: none"> ● Chairman ● Director 	30,000 Baht 20,000 Baht	30,000 Baht 20,000 Baht
Meeting Allowance For non-executive director (Baht : time) (pay only to meeting attendee) <u>Board of Directors</u> <ul style="list-style-type: none"> ● Chairman ● Director 	20,000 Baht 15,000 Baht	20,000 Baht 15,000 Baht
<u>Audit Committee</u> <ul style="list-style-type: none"> ● Chairman ● Director 	22,500 Baht 15,000 Baht	22,500 Baht 15,000 Baht

Position	2025 (proposed year)	2024
<u>Nomination and Remuneration Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Corporate Governance and Sustainable Development Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht
<u>Risk Management Committee</u>		
● Chairman	15,000 Baht	15,000 Baht
● Director	10,000 Baht	10,000 Baht

For the policy of paying bonuses to independent directors and non-executive directors (whole board), the Company pays no more than 0.5% of the announced dividend amount. The monthly remuneration, meeting allowance and other benefits, the total amount must not exceed 4 Million Baht. By assigning the Board of Directors or the person assigned by the Board of Directors to consider and allocate bonuses to independent directors and non-executive directors.

In the year 2024, the total remuneration and bonus of the Board of Directors and sub-committees was approximately 3.16 Million Baht, not exceeding the rate approved by the above meeting of shareholders. Details are as shown in the Annual Report 2024 (Form 56-1 One Report) in page 168.

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda. The Chairman proposed to the meeting to consider and approve the remuneration of directors for the year 2025

Meeting Resolution The meeting considered and resolved to approve the remuneration of directors for the year 2025 with a vote of not less than two-thirds of the total number of votes of the shareholders who attend the meeting and have the right to vote as follow:

Agree	357,757,714	votes	% equivalent to	100.0000
Disagree	0	votes	% equivalent to	0.0000
Abstain	0	votes	% equivalent to	0.0000

Agenda 7 To consider and approve the appointment auditors and audit fee for the year 2025

The Chairman assigned Ms. Chompunuch Meevang, the Company Secretary, to inform the Meeting of the details regarding this agenda.

The Company Secretary informed the Meeting that according to Section 120 of the Public Company Limited Act B.E. 2535 (1992) (as amended), which stipulates that the Annual General Meeting of

Shareholders shall appoint auditors and determine audit fees every year. In appointing the auditor, the same auditor may be reappointed.

The Audit Committee has considered and approved the selection of auditors from EY Office Limited to be the auditors of the Company and its subsidiaries for the year 2025, which has been the same auditor for the fifth consecutive year. EY Office Limited has satisfactorily performed its duties to the Company in accordance with the auditing standards and provided useful opinions useful opinions to the Company and independent and agreed that the audit fee proposed by EY Office Limited was appropriate, when compared to the scope of service and workload.

With careful consideration Audit Committee, the Board of Directors deemed it appropriate to propose to the Annual General Meeting of Shareholders to appoint auditors from EY Office Limited, which is the same auditor as the Company's subsidiaries, whereby one of the following auditors will be appointed as the auditor of the Company for the year 2025.

- | | |
|-----------------------------------|---|
| 1. Ms. Siriwan Nitdamrong | Certified Public Accountant No. 5906 and / or |
| 2. Ms. Kamonthip Lertwitworathep | Certified Public Accountant No. 4377 and / or |
| 3. Mrs. Sarinda Hirunprasurtwutti | Certified Public Accountant No. 4799 and / or |
| 4. Mr. Somsak Chiratdhitiampyong | Certified Public Accountant No. 8874 |

Ms. Siriwan Nitdamrong, Certified Public Accountant No. 5906, who has signed the company's financial statements since the 1st quarter of 2021 until the 2024 annual financial statements. All above four auditors are qualified and has no relationship or any conflict of interest with the Company, its subsidiaries and associates, management, major shareholders or any person related to such person. Therefore, there is independence in auditing and express an opinion on the Company's financial statements, its subsidiaries and associates including the certified auditors as above, no auditors have performed the audit duties of the Company for more than the period specified in the relevant announcement. (Profiles of the Auditors proposed for the year 2025, **Attachment No. 4**)

The Board of Directors also deemed it appropriate to propose to the Annual General Meeting of Shareholders to approve the audit fees of the Company for the year 2025 (not include non-audit fee) as follows:

List of services	2025 (proposed year)	2024	Increase/(Decrease)
Audit fee of the Company	2,180,000	1,890,000	290,000

The Chairman gave the shareholders an opportunity to ask questions and express their opinions. In this regard, there were no shareholders asking or commenting on this agenda.

The Chairman proposed to the meeting to consider and approve the appointment auditors and audit fee for the year 2025

Meeting Resolution The meeting considered and resolved to approve the appointment auditors and audit fee for the year 2025 with the following votes:

Agree	355,741,464	votes	% equivalent to	99.9954
Disagree	0	votes	% equivalent to	0.0000
Abstain	16,250	votes	% equivalent to	0.0046

Agenda 8 To consider any other matters (if any)

-None-

The Chairman gave the shareholders an opportunity to ask questions and express their additional opinions.

1. Mr. Wira Pateepamornrat, a shareholder, inquired about the expected increase in sales from the company's newly established partnerships.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, responded that as previously announced, the company signed a collaboration agreement relating to ophthalmic drugs. A registration meeting is scheduled for May 7, 2025, and it is estimated that the regulatory approval process will take approximately one year. Following approval from the U.S. Food and Drug Administration (US FDA) which is expected within this year—the registration process will begin, and product launch is anticipated in 2027. Based on the company's sales forecast, the first year of commercialization is expected to generate over THB 100 million, with projected cumulative sales reaching approximately THB 1.5 billion by the tenth year, exclusively from the eye drop products developed in partnership with Zhaoke.

2. Ms. Sukanya Pattanapiboonphan, a shareholder, raised the following questions:

- 1) Does the company have any plans to acquire additional businesses, and what is the timeline?
- 2) Does the company apply a minimum IRR (Internal Rate of Return) policy when evaluating acquisitions?

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, responded that the company currently has no acquisition plans for this year. He explained that the company's strategic vision is currently being fully addressed through four key projects: Gene therapy for Parkinson's disease, Eye drop product development, The listing of its pharmacy business on the Stock Exchange of Thailand, The listing of Nakornpat Inter Hospital and Inter Pharma MedTech Co., Ltd. on the Market for Alternative Investment (MAI). Beyond these projects, the company continues to operate its existing businesses, including nutraceuticals and pharmaceuticals.

3. Mr. Rangsri Chuntharusmi, a shareholder, asked whether the kratom project is still ongoing. If so, he requested an update on its current progress and the expected year of completion.

Dr. Trinnawat Thanitnithiphan, Chief Executive Officer, confirmed that the kratom project is still active. The first product expected to launch is kratom-based cream, containing the active compound mitragynine. Test results have shown promising pain-relieving effects. This project is a collaboration with Prince of Songkla University and is supported by the Thai FDA. It is considered a public-private partnership, involving cooperation between government agencies, academia, and the private sector, particularly Inter Pharma Public Company Limited. In terms of pharmaceutical applications, the company has initiated research into using kratom extract as a substitute for narcotics. The project is currently awaiting research funding approval from the relevant ministry. Once funding is granted, the company will begin Phase 1 clinical research to evaluate the use of mitragynine as a potential narcotic substitute. The kratom cream is expected to be commercially available this year, while drug-substitution research will likely take another 3–4 years to complete.

No shareholders made any suggestions or additional questions. The Chairman thanked all shareholders for taking time to attend the meeting and when there was no other business matter, the Chairman adjourned the meeting at 15.00 hrs.

-Signature-

(Clinical Professor Emeritus Dr. Udom Kachintorn)

Chairman of the Board of Directors

-Signature-

(Ms. Chompunuch Meevang)

Company Secretary